GSE208092

Transcriptome analysis to explore the shared and distinct immune signature between severe COVID-19 and bacterial sepsis

Whole-study status Exploratory only

Dataset can inform exploration but is not strong enough for primary analysis.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

15 case / 4 control samples elsewhere in the study have incomplete or conflicting evidence; they are not included above

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

To profile the landscape of circRNAs in neutrophils of COVID-19 and sepsis patients, we conducted comprehensive expression profiling analysis in a training cohort.

Overall design

Comparative circRNAs expression profiling analysis of RNA-seq data for neutrophils from four healthy donors,five critically ill patients with COVID-19 and ten bacterial sepsis patients.

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
19 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Publication context when PubMed identifiers are already known.

No match found

Metadata Quality Components

Analysis Readiness

Review before analysis
97% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • Secondary RNA assay context should be analyzed separately from ordinary bulk RNA-seq.

Next Steps

  • Review blockers and update sample grouping or dataset selection before analysis.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Exploratory only Dataset can inform exploration but is not strong enough for primary analysis.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Disease context COVID-19, sepsis Disease context came from Normalization rules.
  • Likely case group Sepsis 15 samples
  • Likely control group Healthy control 4 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded for tissue search because it is a biofluid cohort. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Patient biofluid vs healthy control. Specimen: Biofluid. Comparison suitability: 20%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Interpreted disease metadata: COVID-19, Sepsis.
  • Processed data is available for downstream review.

Cautions

  • Downgraded for tissue search because it is a biofluid cohort.
  • Blood, plasma, or serum cohort downgraded because this ranking targets tissue tumor-vs-normal comparisons.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

89 fields

Sample Group Preview

19 rows shown
Show Hide
Study totals: Case 15 | Control 4 | Unassigned 0 | Excluded 0 | Ambiguous 0 19 rows shown
Group Role Accession Title Source / characteristics Reason
Sepsis Case GSM6336980 S1 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: Sepsis Case marker detected.
Sepsis Case GSM6336981 S2 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: Sepsis Case marker detected.
Sepsis Case GSM6336982 S3 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: Sepsis Case marker detected.
Sepsis Case GSM6336983 S4 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: Sepsis Case marker detected.
Sepsis Case GSM6336984 S5 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: Sepsis Case marker detected.
Sepsis Case GSM6336985 S6 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: Sepsis Case marker detected.
Sepsis Case GSM7527887 S7 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: Sepsis Case marker detected.
Sepsis Case GSM7527888 S8 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: Sepsis Case marker detected.
Sepsis Case GSM7527889 S9 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: Sepsis Case marker detected.
Sepsis Case GSM7527890 S10 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: Sepsis Case marker detected.
COVID-19 Case GSM7527891 COVID1 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: COVID-19 Case marker detected.
COVID-19 Case GSM7527892 COVID2 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: COVID-19 Case marker detected.
COVID-19 Case GSM7527893 COVID3 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: COVID-19 Case marker detected.
COVID-19 Case GSM7527894 COVID4 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: COVID-19 Case marker detected.
COVID-19 Case GSM7527895 COVID5 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: COVID-19 Case marker detected.
Healthy control Control GSM6336976 HC1 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: Healthy control Sample-local control marker detected.
Healthy control Control GSM6336977 HC2 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: Healthy control Sample-local control marker detected.
Healthy control Control GSM6336978 HC3 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: Healthy control Sample-local control marker detected.
Healthy control Control GSM6336979 HC4 Peripheral blood Tissue: Peripheral blood; Cell type: Neutrophils; Disease state: Healthy control Sample-local control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.